Exelixis (EXEL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
2 Nov, 2026Executive summary
Q3 2026 revenue rose 10% YoY to $658.7M; GAAP net income was $218.1M and diluted EPS was $0.85.
Cabozantinib growth and broad zanzalintinib development underpin oncology franchise expansion, alongside disciplined R&D investment and shareholder returns.
Financial highlights
Q3 net product revenue was $604.9M, up 11% YoY; collaboration revenue was $53.8M, including $51.8M in cabozantinib royalties.
GAAP operating expenses were $390.3M: R&D $209.5M and SG&A $154.6M; SG&A growth reflected personnel, clinical, marketing and legal costs.
Non-GAAP net income was $240.2M and diluted EPS was $0.94, excluding stock-based compensation net of tax.
Q3 operating income was $268.4M versus $236.5M YoY; GAAP net income was $218.1M versus $193.6M.
Outlook and guidance
FY 2026 revenue guidance remains $2.500B–$2.550B, including net product revenue of $2.300B–$2.350B; guidance excludes potential zanzalintinib CRC approval and launch revenue.
FY 2026 COGS guidance is ~4% of net product revenue; R&D guidance is $825M–$875M and SG&A is $575M–$625M.
FY 2026 effective tax-rate guidance fell to 16%–18% from 21%–23%.
STELLAR-304 top-line results are expected in Q1 2027; positive results could support a second zanzalintinib NDA.
STELLAR-303 NDA review was extended; the updated PDUFA target date is March 3, 2027.
Latest events from Exelixis
- Zanza’s seven pivotal trials anchor a disciplined shift toward multiple franchises.EXEL
Jefferies Global Healthcare Conference - Zanzalintinib expansion and a 1Q RCC readout anchor the next growth phase.EXEL
UBS Global Biopharma Conference 2026 - Zanzalintinib’s 2027 milestones anchor a broader, multi-franchise growth strategy.EXEL
Stifel 2026 Healthcare Conference 2026 - CABO growth funds a broad zanza pipeline while R&D, BD and buybacks remain concurrent priorities.EXEL
3rd Annual Guggenheim Healthcare Innovation Conference - Zanzalintinib’s pivotal pipeline and CRC launch plans anchor a multi-franchise growth strategy.EXEL
Morgan Stanley 24th Annual Global Healthcare Conference - Q4 revenue rose 13% as CABOMETYX expansion and pipeline growth shaped 2024 priorities.EXEL
Q4 2023 - CABOMETYX and zanzalintinib drive growth across oncology franchises, with AI boosting efficiency.EXEL
Citigroup’s Biopharma Back to School Summit 2026 - CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans.EXEL
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 11% to $629M, with strong cabozantinib sales and zanzalintinib NDA review.EXEL
Q2 2026